SYRE SPYRE THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, SPYRE THERAPEUTICS INC reported revenue of n/a, net income of −$36.2M and diluted EPS of n/a; for the fiscal year ended December 2025 revenue was $0.

SYRE annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $0, gross profit n/a, operating income −$210M, net income −$155M (margin n/a), EPS n/a
• Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$209M, net income −$208M (margin n/a), EPS n/a
• Fiscal year ended Dec 2023: revenue $886K, gross profit n/a, operating income −$242M, net income −$339M (margin -38238.1%), EPS $13.76
• Fiscal year ended Dec 2022: revenue $2.33M, gross profit n/a, operating income −$84.8M, net income −$83.8M (margin -3598.8%), EPS −$24.86
• Fiscal year ended Dec 2021: revenue $18.7M, gross profit n/a, operating income −$65.6M, net income −$65.8M (margin -351.1%), EPS −$25.02

SYRE quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue n/a, net income −$36.2M, EPS n/a
• Quarter ended Mar 31, 2026: revenue n/a, net income −$69.0M, EPS −$0.74
• Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$62.5M, EPS n/a
• Quarter ended Sep 30, 2025: revenue n/a, net income −$11.2M, EPS n/a
• Quarter ended Jun 30, 2025: revenue n/a, net income −$36.7M, EPS n/a
• Quarter ended Mar 31, 2025: revenue n/a, net income −$44.8M, EPS n/a
• Quarter ended Dec 31, 2024 (from the annual report): revenue $0, net income −$56.3M, EPS n/a
• Quarter ended Sep 30, 2024: revenue $0, net income −$69.0M, EPS $1.06
• Quarter ended Jun 30, 2024: revenue $0 (down 100.0% year over year), net income −$38.8M, EPS $0.59
• Quarter ended Mar 31, 2024: revenue $0 (down 100.0% year over year), net income −$43.9M, EPS $0.72
• Quarter ended Dec 31, 2023 (from the annual report): revenue $0 (down 100.0% year over year), net income −$63.2M, EPS −$22.35
• Quarter ended Sep 30, 2023: revenue $0 (down 100.0% year over year), net income −$40.1M, EPS $0.86
• Quarter ended Jun 30, 2023: revenue $688K (up 10.1% year over year), net income −$217M, EPS $40.14
• Quarter ended Mar 31, 2023: revenue $198K (down 85.5% year over year), net income −$18.4M, EPS −$4.89
• Quarter ended Dec 31, 2022 (from the annual report): revenue $168K (down 95.4% year over year), net income −$18.8M, EPS −$19.38
• Quarter ended Sep 30, 2022: revenue $174K (down 87.6% year over year), net income −$18.2M, EPS −$4.84
• Quarter ended Jun 30, 2022: revenue $625K (down 95.4% year over year), net income −$22.3M, EPS −$0.27
• Quarter ended Mar 31, 2022: revenue $1.36M, net income −$24.4M, EPS −$0.37
• Quarter ended Dec 31, 2021 (from the annual report): revenue $3.64M, net income −$20.4M, EPS −$24.33
• Quarter ended Sep 30, 2021: revenue $1.40M, net income −$20.3M, EPS −$0.31

SYRE cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$169M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$157M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$99.9M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$80.1M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$53.7M, share buybacks n/a

SYRE balance sheet

• Jun 30, 2026: cash $162M, total assets $1.17B, total liabilities $71.9M, shareholders' equity $1.10B
• Mar 31, 2026: cash $97.2M, total assets $764M, total liabilities $93.1M, shareholders' equity $671M
• Dec 31, 2025: cash $85.7M, total assets $778M, total liabilities $62.5M, shareholders' equity $715M
• Sep 30, 2025: cash $64.9M, total assets $505M, total liabilities $49.5M, shareholders' equity $455M
• Jun 30, 2025: cash $81.7M, total assets $539M, total liabilities $83.1M, shareholders' equity $456M
• Mar 31, 2025: cash $48.5M, total assets $570M, total liabilities $87.2M, shareholders' equity $483M
• Dec 31, 2024: cash $89.4M, total assets $608M, total liabilities $90.7M, shareholders' equity $518M
• Sep 30, 2024: cash $71.6M, total assets $421M, total liabilities $93.7M, shareholders' equity $327M

What is SYRE's revenue?

SPYRE THERAPEUTICS INC reported $0 of revenue for the fiscal year ended December 2025.

Is SYRE profitable?

No. SPYRE THERAPEUTICS INC lost $179M over the last four quarters.

SYRE ownership and insider trades · All stocks